Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Schaller

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Plos Pathogens|December 17, 2011
HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiencyTorsten Schaller, Karen E Ocwieja, Jane Rasaiyaah, et al.
Blood Cancer Journal|October 21, 2018
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimensGeorge Z Rassidakis, Nikolas Herold, Ida Hed Myrberg, et al.
Journal of Internal Medicine|August 8, 2022
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trialMartin Jädersten, Ingrid Lilienthal, Nikolaos Tsesmetzis, et al.
Pharmacological Research|October 18, 2025
Safety and efficacy of monoclonal antibody therapy in patients with chronic herpes simplex virus-2 genital infections: MATCH-2, a randomized double-blinded, parallel-group phase 2 multi-center trialHans-Jürgen Stellbrink, Torsten Schaller, Kerstin Sturm, et al.
EMBO Molecular Medicine|January 18, 2020
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacySean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, et al.
Nature Medicine|January 10, 2017
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignanciesNikolas Herold, Sean G Rudd, Linda Ljungblad, et al.
Nature Chemical Biology|July 22, 2020
Development of a chemical probe against NUDT15Si Min Zhang, Matthieu Desroses, Anna Hagenkort, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Plos Pathogens|December 17, 2011
HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiencyTorsten Schaller, Karen E Ocwieja, Jane Rasaiyaah, et al.
Blood Cancer Journal|October 21, 2018
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimensGeorge Z Rassidakis, Nikolas Herold, Ida Hed Myrberg, et al.
Journal of Internal Medicine|August 8, 2022
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trialMartin Jädersten, Ingrid Lilienthal, Nikolaos Tsesmetzis, et al.
Pharmacological Research|October 18, 2025
Safety and efficacy of monoclonal antibody therapy in patients with chronic herpes simplex virus-2 genital infections: MATCH-2, a randomized double-blinded, parallel-group phase 2 multi-center trialHans-Jürgen Stellbrink, Torsten Schaller, Kerstin Sturm, et al.
EMBO Molecular Medicine|January 18, 2020
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacySean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, et al.
Nature Medicine|January 10, 2017
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignanciesNikolas Herold, Sean G Rudd, Linda Ljungblad, et al.
Nature Chemical Biology|July 22, 2020
Development of a chemical probe against NUDT15Si Min Zhang, Matthieu Desroses, Anna Hagenkort, et al.
Pageof 7